OPKO Health Enrolls First Patient in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes

Genetics Investing

OPKO Health (NASDAQ:OPK) has enrolled the first patient in a Phase 2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type 2 diabetes and obesity. As quoted in the press release: “Our confidence in this program is supported by the earlier Phase 2 data …

As quoted in the press release:

“Our confidence in this program is supported by the earlier Phase 2 data and we are enthusiastic to be initiating this study in type 2 diabetics to evaluate the effects of a refined dosing regimen of oxyntomodulin on glucose control and weight loss in preparation for a pivotal Phase 3 program. The dual agonist activity of OPK88003 may provide improved benefits in the treatment of diabetes, resulting in better glucose control and improved long-term cardiovascular outcomes, and we believe it has the potential to offer improved benefits compared with the current once-weekly GLP-1 therapies in a growing diabetes market,” stated Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health.

Click here to read the full press release.

cardiovascular diabetes diabetics first patient health opko health patient weight loss Genetics Investing